|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2324252627282930313233...4041» |
- Enrollment change: Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=45, Recruiting, Sponsor: University of Iowa
N=30 --> 45
- || Betaseron (IFN-β-1b) / Bayer
Enrollment closed, Adherence: China Betaferon Adherence, Coping and Nurse Support Study (clinicaltrials.gov) - Oct 26, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: Bayer
N=30 --> 45 Recruiting --> Active, not recruiting
- ||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Reflex: REFLEXION: Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (clinicaltrials.gov) - Oct 24, 2013
P3, N=402, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Enrollment closed: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - Oct 24, 2013
P3, N=1734, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Xeomin (incobotulinumtoxinA) / Merz Pharma
New P4 trial: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 22, 2013
P4, N=30, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
- Enrollment change: Sodium Intake in Multiple Sclerosis (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=132, Completed, Sponsor: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Completed --> Active, not recruiting N=70 --> 132
- Trial completion: Sodium Intake in Multiple Sclerosis (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=132, Completed, Sponsor: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
N=70 --> 132 Recruiting --> Completed
- |||| Betaseron (IFN-β-1b) / Bayer
Enrollment open: BENEFIT 11: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis (clinicaltrials.gov) - Oct 17, 2013
P4, N=400, Recruiting, Sponsor: Bayer
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| GSK239512 / GSK
Enrollment closed: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 16, 2013
P2, N=114, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P2 trial: MSPi: Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments (clinicaltrials.gov) - Oct 15, 2013
P2, N=10, Active, not recruiting, Sponsor: Oregon Health and Science University
- ||||| plovamer (CO-14) / EMD Serono
New P2 trial: EMR200575-001: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (clinicaltrials.gov) - Oct 14, 2013
P2, N=550, Recruiting, Sponsor: EMD Serono
- |||||| teriflunomide / Generic mfg.
Enrollment open, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 13, 2013
P3, N=68, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed: MSPi: Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments (clinicaltrials.gov) - Oct 13, 2013
P2, N=10, Active, not recruiting, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Trial completion, HEOR: EMR200077-511: Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 12, 2013
P=N/A, N=306, Completed, Sponsor: Merck KGaA
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion, HEOR: EMR200077-507: To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 12, 2013
P=N/A, N=150, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: EMR 200077_502: Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina (clinicaltrials.gov) - Oct 12, 2013
P=N/A, N=252, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Betaseron (IFN-β-1b) / Bayer
Enrollment change: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (clinicaltrials.gov) - Oct 7, 2013
P=N/A, N=1300, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed N=2000 --> 1300
- Enrollment closed: Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 7, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
N=2000 --> 1300 Not yet recruiting --> Active, not recruiting
- | New P1/2 trial: FARMS-2: Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior (clinicaltrials.gov) - Oct 6, 2013
P1/2, N=60, Active, not recruiting, Sponsor: University of Illinois at Urbana-Champaign
- Enrollment open: Longitudinal Study of Outcomes Measures in ALS Trials (clinicaltrials.gov) - Oct 6, 2013
P=N/A, N=100, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- sirolimus / Generic mfg.
Trial initiation date: Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream (clinicaltrials.gov) - Oct 3, 2013
P1, N=15, Recruiting, Sponsor: Le Bonheur Children's Hospital
Not yet recruiting --> Recruiting Initiation date: Jun 2013 --> Oct 2013
- glatiramer acetate / Generic mfg.
Enrollment change: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2013
P=N/A, N=17, Completed, Sponsor: University of California, San Francisco
Initiation date: Jun 2013 --> Oct 2013 N=30 --> 17
- sirolimus / Generic mfg.
Enrollment open: Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream (clinicaltrials.gov) - Oct 3, 2013
P1, N=15, Recruiting, Sponsor: Le Bonheur Children's Hospital
N=30 --> 17 Not yet recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Trial completion: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2013
P=N/A, N=17, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Mavenclad (cladribine) / EMD Serono
Trial initiation date: CLARITY: A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 29, 2013
P3, N=1326, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed Initiation date: Jan 2005 --> Apr 2005
- Clinical data, Adverse events: Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=3000, Recruiting, Sponsor: Elliot Lander
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis (clinicaltrials.gov) - Sep 26, 2013
P3, N=397, Completed, Sponsor: Allergan
Initiation date: Jan 2005 --> Apr 2005 Active, not recruiting --> Completed
- modafinil / Generic mfg.
Trial completion: Modafinil in Multiple Sclerosis (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=20, Completed, Sponsor: Kessler Foundation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- riluzole / Generic mfg.
Trial completion: Neuroprotection With Riluzole Patients With Early Multiple Sclerosis (clinicaltrials.gov) - Sep 23, 2013
P2, N=43, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment open: Gastroesophageal Reflux Treatment in Scleroderma (clinicaltrials.gov) - Sep 23, 2013
P3, N=250, Recruiting, Sponsor: Khon Kaen University
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment closed: Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA) (clinicaltrials.gov) - Sep 18, 2013
P1/2, N=63, Active, not recruiting, Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis (clinicaltrials.gov) - Sep 17, 2013
P1/2, N=18, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting Suspended --> Completed
- | everolimus / Generic mfg.
Trial completion: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Sep 16, 2013
P1/2, N=20, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Suspended --> Completed Active, not recruiting --> Completed
- Enrollment open, MRI: Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=30, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P3 trial: Safety and Efficacy of Fingolimod in MS Patients in China (clinicaltrials.gov) - Sep 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- Enrollment change: Collection of Blood Samples for DNA in Motor Neuron Disease (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=23, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting N=60 --> 23
- Trial completion: Collection of Blood Samples for DNA in Motor Neuron Disease (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=23, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=60 --> 23 Recruiting --> Completed
- |||||||||| Plegridy (PEG-interferon ?-1a) / Biogen
New P3 trial: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Sep 9, 2013
P3, N=200, Recruiting, Sponsor: Biogen Idec
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: SKORE: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (clinicaltrials.gov) - Sep 4, 2013
P=N/A, N=300, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- Preclinical, Trial termination: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2013
P2, N=50, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Terminated; The Study was terminated because there was insufficient data to complete the study objectives
- New P2/3 trial: Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 29, 2013
P2/3, N=14, Active, not recruiting, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
- | pirfenidone / Generic mfg.
New P2 trial: Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) (clinicaltrials.gov) - Aug 29, 2013
P2, N=50, Recruiting, Sponsor: InterMune
- New P1 trial: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2013
P1, N=20, Recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
- | pirfenidone / Generic mfg.
Enrollment open: Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) (clinicaltrials.gov) - Aug 29, 2013
P2, N=50, Recruiting, Sponsor: InterMune
Recruiting --> Terminated; The Study was terminated because there was insufficient data to complete the study objectives Not yet recruiting --> Recruiting
- New P1 trial: SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) - Aug 28, 2013
P1, N=6, Not yet recruiting, Sponsor: North Bristol NHS Trust
- Trial completion: Telephone Intervention for Pain Study (TIPS) (clinicaltrials.gov) - Aug 28, 2013
P=N/A, N=207, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| New P4 trial: Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) - Aug 27, 2013
P4, N=240, Recruiting, Sponsor: Allergan
- Trial withdrawal: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (clinicaltrials.gov) - Aug 26, 2013
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=200 --> 0
- ||| Enrollment change: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Aug 26, 2013
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
N=200 --> 0 N=500 --> 54